Evidence map›Paper›PMID 27125955›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2016

Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.

A M Giovannetti, E Pietrolongo, A Giordano, V Cimino, A Campanella, G Morone, A Fusco, A Lugaresi, P Confalonieri, F Patti and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Understanding quality of life across different clinical subtypes of multiple sclerosis: a thematic analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

A M GiovannettiUnit of Neuroimmunology, and Neuromuscular Diseases, Foundation IRCCS Neurological Institute C. Besta, Milan, Italy.
E PietrolongoDepartment of Neuroscience, Imaging and Clinical Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy.
A GiordanoUnit of Neuroepidemiology, Foundation IRCCS Neurological Institute C. Besta, Milan, Italy.
V CiminoMS Centre, Neurology Clinic, University Hospital Policlinico Vittorio Emanuele, Catania, Italy.
A CampanellaScientific Direction, Foundation IRCCS Neurological Institute C. Besta, Milan, Italy.
G MoroneMultiple Sclerosis Unit, IRCCS S. Lucia Foundation, Rome, Italy.
A FuscoMultiple Sclerosis Unit, IRCCS S. Lucia Foundation, Rome, Italy.
A LugaresiDepartment of Neuroscience, Imaging and Clinical Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy.
P ConfalonieriUnit of Neuroimmunology, and Neuromuscular Diseases, Foundation IRCCS Neurological Institute C. Besta, Milan, Italy.
F PattiMS Centre, Neurology Clinic, University Hospital Policlinico Vittorio Emanuele, Catania, Italy.
M G GrassoMultiple Sclerosis Unit, IRCCS S. Lucia Foundation, Rome, Italy.
M PonzioDepartment of Research, Fondazione Italiana Sclerosi Multipla (FISM), Genoa, Italy.
S VeroneseFARO Charitable Foundation, Turin, Italy.
A SolariUnit of Neuroepidemiology, Foundation IRCCS Neurological Institute C. Besta, Milan, Italy. alessandra.solari@istituto-besta.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIndividualized quality of life (QoL) measures differ from traditional inventories in that QoL domains/weights are not predetermined, but identified by the individual. We assessed practicability of the Schedule for the Evaluation of Individual QoL-Direct Weighting (SEIQoL-DW) interview in severely affected multiple sclerosis (MS) patients; the key QoL dimensions identified; and the correlation of the SEIQoL-DW index score with standard patient-reported outcome measures (PROMs).

methodsParticipants were people with severe MS who performed the baseline visit of the PeNSAMI trial (ISRCTN73082124). The SEIQoL-DW was administered at the patient's home by a trained examiner. Patients then received the following PROMs: the Core-Palliative care Outcome Scale (Core-POS), the Palliative care Outcome Scale-Symptoms-MS (POS-S-MS), the European Quality of Life Five Dimensions-3L (EQ-5D-3L), and the Hospital Anxiety and Depression Scale (HADS).

resultsOf 59 enrolled patients, 11 (19 %) did not receive the SEIQoL-DW (and the other PROMs) because of severe cognitive compromise or inability to communicate. SEIQoL-DW administration was completed and deemed valid in all 48 cases (mean age 60 years, 58 % women, median Expanded Disability Status Scale score 8.5). Mean SEIQoL-DW index score was 59.1 (SD 25.5). The most commonly nominated SEIQoL-DW areas were family (94 % of the patients), relationships, and leisure activities (both 65 %). Core-POS and POS-S-MS contained 70 % of the SEIQoL-DW-nominated areas. Nevertheless, correlations between SEIQoL-DW index, Core-POS, and POS-S-MS (and the other PROMs) were negligible.

conclusionsIndividualized QoL can be assessed in severely affected MS patients, providing information that is not tracked by the standard inventories Core-POS, POS-S-MS, EQ-5D-3L, and HADS.

Indexed as

Sickness Impact ProfileAdolescentAdultAgedFemaleHumansMaleMiddle AgedMultiple SclerosisSurveys and QuestionnairesYoung AdultIndividualized measureOutcome measurePalliative carePrimary progressive multiple sclerosisQuality of lifeSecondary progressive multiple sclerosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.